查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988446

巨细胞病毒检测市场：2026-2032年全球市场预测（按产品类型、检测类型、检体类型、应用和最终用户划分）

Cytomegalovirus Tests Market by Product, Test Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，巨细胞病毒检测市场价值将达到 7.3124 亿美元，到 2026 年将成长至 7.8811 亿美元，到 2032 年将达到 12.9201 亿美元，年复合成长率为 8.47%。

主要市场统计数据
基准年 2025 7.3124亿美元
预计年份：2026年 7.8811亿美元
预测年份 2032 1,292,010,000 美元
复合年增长率 (%) 8.47%

临床因素、诊断重点和操作考虑因素的策略整合塑造了现代巨细胞病毒检测和部署。

随着诊断技术和治疗途径的进步，巨细胞病毒(CMV) 检测在临床和公共卫生领域的重要性日益凸显。早期准确识别 CMV 感染对于新生儿护理、移植患者管理、捐赠者筛检和产前风险评估仍然至关重要。随着对精准诊断和快速照护现场方案的需求不断增长，临床、实验室、研究和商业领域的相关人员需要将技术能力、应用场景优先顺序和监管要求清晰整合，以指导投资和营运决策。

分子诊断和即时诊断技术的进步、监管部门对检验的日益重视以及检体的柔软性正在改变巨细胞病毒检测的临床应用。

鉅细胞病毒 (CMV) 检测领域正经历多项变革，其驱动力包括技术成熟、临床重点转变以及对快速有效检测结果日益增长的需求。分子扩增技术的灵敏度和处理能力不断提升，使得在多种检体基质中实现早期检测成为可能，并能应对传统血清学检测无法涵盖的更广泛的临床场景。同时，即时检测 (PoC) 和简化的抗原检测方法正朝着患者现场应用的方向发展，降低了门诊和新生儿病房等需要即时做出治疗决策的场所进行及时诊断的门槛。

美国近期关税措施对巨细胞病毒检测诊断供应链、筹资策略及製造商采购韧性的影响。

美国近期推出的关税政策进一步加剧了全球诊断组件和设备供应链的复杂性。对进口试剂、仪器零件及相关耗材征收关税可能会增加製造商和检查室营运商的总成本，促使他们重新评估筹资策略和库存管理。对于依赖跨境供应链的企业而言，这些措施凸显了其日益增长的需求，即需要实现采购来源多元化和采用近岸外包方案，以降低关税相关成本波动带来的影响。

全面的細項分析揭示了产品模式、测试结果、临床应用、最终用户工作流程和检体基质如何决定诊断的价值和普及程度。

按产品、检测类型、应用、最终用户和检体类型细分鉅细胞病毒 (CMV) 诊断，可以揭示其价值和需求如何因临床背景和技术特性而异。按产品划分，这些包括抗原检测、核酸增幅检查和血清学检测。抗原检测方法大致分为萤光和侧向层析法，两者在速度和灵敏度方面各有侧重，以满足不同的需求。萤光通常用于需要更高分析灵敏度的中心检查室，而侧向层析抗原检测则满足在患者所在地进行快速筛检的需求。核酸扩增方法包括数位聚合酵素链锁反应(PCR)、等温扩增和即时PCR。即时PCR因其在灵敏度、处理能力和法规相容性方面的平衡而仍然是亲和性的技术。血清学检测，包括化学冷光免疫检测、酵素免疫分析法(ELISA) 和侧向流动免疫检测，可提供有关宿主免疫反应的补充信息，并在筛检和流行病学监测中发挥核心作用。

美洲、欧洲、中东和非洲以及亚太地区的诊断环境和基础设施存在差异，导致各地区的部署路径各不相同。

区域趋势影响着技术应用、报销机制、检查室基础设施和临床指南，从而在不同地区造成了不同的策略挑战。在美洲，诊断生态系统的特点是检查室网路完善、分子诊断平台已广泛应用，以及临床指引强调对高风险族群进行早期检测。这些系统评估的检测方法需具备临床效用、扩充性和与电子健康记录的兼容性，同时也要求强大的供应链和合规性。

现有平台营运商、专家创新者和通路合作伙伴之间的竞争和策略行动，决定了检测的可用性和临床有效性。

鉅细胞病毒 (CMV) 检测领域的竞争格局呈现出平台型製造商、专业方法开发人员和专注于特定临床应用的新兴创新者三者并存的态势。成熟的诊断公司往往利用其丰富的产品系列、良好的监管记录和全球分销网络，提供从高通量检测系统到照护现场设备等一系列整合解决方案。这些成熟公司正积极投资于临床检验研究、平台相容性以及生命週期服务合同，以维护客户忠诚度并满足医院和合约实验室的需求。

为产业主管提供可操作的、高优先顺序的行动方案，以提高巨细胞病毒诊断解决方案的临床可靠性、韧性和普及性。

产业领导者可以采取果断行动，增强临床对鉅细胞病毒 (CMV) 检测的信心，加速其普及，并建立稳健的供应和商业模式。优先进行强有力的临床检验研究，以证明其在目标应用领域的效用，将有助于增强支付方和医疗服务提供者的信心。产品设计应符合目标终端使用者的实际情况，例如最大限度地减少诊所的工作时间，并确保诊断检查室的自动化和处理能力，这将降低推广应用的障碍，并支援其融入临床工作流程。

采用透明且可重复的研究途径，结合严格的二手文献综述、与主要相关人员的访谈以及基于情境的检验。

本研究采用实证方法，结合系统性的二手文献综述和主导访谈，以确保研究结果的平衡性和可重复性。二手文献综述涵盖了同侪审查的临床文献、监管指南文件和技术白皮书，旨在梳理检测的性能特征、建议的临床工作流程和检验标准。定性访谈则包括对临床医生、实验室经理、采购经理和技术开发人员的结构化访谈，以获取关于推广应用驱动因素、营运限制和未满足需求的第一手观点。

综合结论强调，检验的创新、营运韧性和实证部署是有效巨细胞病毒诊断策略的支柱。

鉅细胞病毒 (CMV) 诊断是一个动态领域，临床需求、技术创新和营运要求在此交汇融合。分子扩增和照护现场抗原检测技术的进步正在拓展 CMV 及时识别的应用场景，从而显着改善新生儿、移植患者和孕妇的预后。同时，日益严格的监管、供应链的限制以及区域差异要求研发人员和采用者采取以实证医学为基础、灵活且优先考虑临床效用和服务连续性的策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：巨细胞病毒检测市场：依产品划分

  • 抗原检测
    • 萤光
    • 横向流动化验
  • 核酸增幅检查
    • 数位聚合酵素链锁反应
    • 等温扩增
    • 即时聚合酵素链锁反应
  • 血清学检测
    • 化学冷光免疫检测
    • 酵素免疫分析法
    • 侧向流动免疫检测

第九章：巨细胞病毒检测市场（依检测类型划分）

  • 定性
  • 定量

第十章：巨细胞病毒检测市场（检体类型划分）

  • 唾液
  • 组织
  • 尿
  • 全血

第十一章：巨细胞病毒检测市场：依应用划分

  • 诊断
  • 捐赠者筛检
  • 产前检查
  • 筛检

第十二章：巨细胞病毒检测市场：依最终用户划分

  • 诊所
  • 检查室
  • 医院
  • 研究机构

第十三章：巨细胞病毒检测市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：巨细胞病毒检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：巨细胞病毒检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国巨细胞病毒检测市场

第十七章：中国巨细胞病毒检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbexa Ltd.
  • Abbott Laboratories
  • Accubiotech Co., Ltd
  • AdvaCare Pharma USA
  • Agilent Technologies, Inc.
  • Atlas Medical GmbH
  • Bio-Rad Laboratories, Inc.
  • Biogenix Inc. Pvt. Ltd.
  • CLONIT srl
  • Creative Diagnostics
  • CTK Biotech Inc. by SSI Diagnostica A/S
  • Diasorin SpA
  • Elabscience Bionovation Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hangzhou Realy Tech Co., Ltd.
  • Intec Products, Inc.
  • IQ Products BV
  • Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
  • Meridian Bioscience, Inc. by SD Biosensor
  • Thermo Fisher Scientific Inc
Product Code: MRR-6B0EA07975A5

The Cytomegalovirus Tests Market was valued at USD 731.24 million in 2025 and is projected to grow to USD 788.11 million in 2026, with a CAGR of 8.47%, reaching USD 1,292.01 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 731.24 million
Estimated Year [2026] USD 788.11 million
Forecast Year [2032] USD 1,292.01 million
CAGR (%) 8.47%

A strategic synthesis of clinical drivers, diagnostic priorities, and operational considerations shaping contemporary cytomegalovirus testing and adoption

The clinical and public health implications of cytomegalovirus (CMV) testing have intensified as diagnostic technologies and care pathways evolve. Early and accurate identification of CMV infection remains a cornerstone of neonatal care, transplant patient management, donor screening, and prenatal risk mitigation. With growing emphasis on precision diagnostics and rapid point-of-care solutions, stakeholders across clinical, laboratory, research, and commercial domains require a clear synthesis of technological capabilities, use-case priorities, and regulatory expectations to guide investment and operational decisions.

This executive overview synthesizes current drivers and constraints shaping CMV testing adoption, emphasizing the interplay between assay performance characteristics and real-world clinical requirements. It highlights advances in assay modalities, the implications of regulatory and reimbursement trends, and the operational considerations that determine adoption in diverse end-user settings. By clarifying the diagnostic value proposition across sample types and clinical applications, this introduction sets the stage for deeper analysis of transformative shifts, policy impacts, segmentation-specific insights, and practical recommendations for decision-makers seeking to optimize diagnostic portfolios and clinical pathways.

How advances in molecular and point-of-care diagnostics, regulatory emphasis on validation, and sample flexibility are reshaping clinical adoption of cytomegalovirus testing

The CMV testing landscape is undergoing multiple transformative shifts driven by technological maturation, changing clinical priorities, and evolving expectations for rapid, actionable results. Molecular amplification techniques have advanced in sensitivity and throughput, enabling earlier detection in diverse sample matrices and supporting a broader set of clinical scenarios beyond traditional serology. Concurrently, point-of-care modalities and simplified antigen detection formats are converging toward near-patient use, lowering the threshold for timely diagnosis in outpatient clinics and neonatal wards where immediate therapeutic decisions are critical.

Regulatory pathways and laboratory accreditation standards are also reshaping product design and deployment. Manufacturers are prioritizing robust validation data, streamlined user workflows, and compatibility with laboratory information systems to meet hospital and reference laboratory requirements. Integration of quantitative readouts alongside qualitative determinations is increasing demand for assays that can support monitoring and therapeutic decision-making, particularly in transplant medicine and prenatal care. Meanwhile, sample type flexibility-expanding beyond whole blood to include urine, saliva, and tissue specimens-has broadened testing prospects and enabled less invasive diagnostic strategies.

These shifts are reinforced by health system priorities that place a premium on diagnostic stewardship, cost-effective screening protocols, and reduced time-to-result. As technologies converge, successful products will be those that balance analytical performance with usability, regulatory readiness, and clear clinical utility. The cumulative effect is a diagnostic environment that rewards interoperability, evidence-based claims, and development strategies that anticipate diverse end-user needs across acute care and community settings.

Implications of recent United States tariff measures on diagnostic supply chains, procurement strategies, and manufacturer sourcing resilience across cytomegalovirus testing

Recent tariff policies enacted by the United States have introduced an additional layer of complexity to the global supply chain for diagnostic components and instruments. Tariffs on imported reagents, instrument parts, and related consumables can increase landed costs for manufacturers and lab operators, prompting reassessment of sourcing strategies and inventory management. For organizations that rely on cross-border supply chains, these measures have heightened the need for supply diversification and nearshoring options to mitigate exposure to duty-related cost volatility.

In response, manufacturers and distributors have explored multiple mitigations including renegotiating supplier contracts, increasing inventory buffers, and accelerating qualification of alternative vendors in low-tariff jurisdictions. Laboratories and health systems have been compelled to evaluate total cost of ownership rather than unit price alone, factoring in logistics, customs delays, and potential downtime risks. Procurement departments are coordinating more closely with clinical stakeholders to prioritize critical assays and to sequence product rollouts in a manner that preserves clinical continuity while managing fiscal constraints.

Policy-driven cost pressures have also influenced strategic decisions around local manufacturing investment and product configuration. Some firms have opted to modularize instrument design to allow assembly or component sourcing in tariff-exempt locations, while others have pursued licensing or contract manufacturing arrangements to preserve market access. As a result, competitive differentiation is increasingly tied to supply chain resilience and the ability to maintain service level agreements under shifting trade conditions. For buyers and planners, the tariff environment underscores the importance of conducting scenario-based procurement planning and maintaining flexible contracts that can accommodate distribution or production changes without compromising clinical operations.

Comprehensive segmentation analysis revealing how product modality, test output, clinical application, end-user workflows, and sample matrices determine diagnostic value and adoption

Deconstructing CMV diagnostics by product, test type, application, end user, and sample type reveals how value and demand vary across clinical contexts and technology attributes. By product, the landscape includes antigen detection tests, nucleic acid amplification tests, and serological assays. Antigen detection formats differentiate by immunofluorescence and lateral flow approaches, each catering to different speed and sensitivity trade-offs; immunofluorescence assays typically serve centralized labs seeking higher analytical sensitivity while lateral flow antigen tests address rapid near-patient screening needs. Nucleic acid amplification encompasses digital polymerase chain reaction, isothermal amplification techniques, and real-time polymerase chain reaction; digital PCR offers absolute quantification useful for monitoring viral load, isothermal methods facilitate simplified instrumentation and rapid turnaround, and real-time PCR continues to be the workhorse for its balance of sensitivity, throughput, and regulatory familiarity. Serological assays, spanning chemiluminescent immunoassay, enzyme-linked immunosorbent assay, and lateral flow immunoassay formats, provide complementary information on host immune response and are central to screening and epidemiologic surveillance.

When viewed by test type, qualitative assays remain important for initial screening and binary diagnostic decisions, while quantitative assays increasingly inform monitoring, risk stratification, and therapeutic management. Application-driven differentiation shows that diagnostic use, donor screening, prenatal testing, and general population screening each place distinct demands on assay attributes such as limit of detection, sample throughput, and ease of use. End-user dynamics further stratify priorities: clinics and hospitals emphasize rapid turnaround and ease of integration into clinical workflows, diagnostic laboratories prioritize high-throughput automation and data management, and research institutes focus on assay flexibility, analytical sensitivity, and compatibility with downstream analyses.

Sample type variation-saliva, tissue, urine, and whole blood-creates opportunities for less invasive testing pathways as well as technical challenges for assay developers in validating performance equivalently across matrices. Urine and saliva offer noninvasive collection suited to neonatal and outpatient screening, whereas tissue and whole blood may be required for definitive diagnosis or for applications demanding high sensitivity. Across these axes, successful product strategies are those that align analytical strengths with the operational realities of target users and the clinical questions each assay seeks to answer.

Regional diagnostic landscapes and infrastructure contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated adoption pathways

Regional dynamics shape technology adoption, reimbursement practices, laboratory infrastructure, and clinical guidelines, creating distinct strategic imperatives across geographies. In the Americas, diagnostic ecosystems are characterized by well-established laboratory networks, adoption of molecular platforms, and clinical guidelines that favor early detection in high-risk populations. These systems reward assays that demonstrate clinical utility, scalability, and compatibility with electronic health records, while also demanding resilient supply chains and regulatory compliance.

In Europe, the Middle East & Africa region, heterogeneity in regulatory environments and healthcare infrastructure leads to varied adoption pathways. Some markets prioritize centralized testing with high-throughput molecular platforms, whereas others emphasize cost-effective, decentralized screening solutions that can function in lower-resource settings. Manufacturers pursuing these geographies must design flexible regulatory strategies and tiered product offerings to address divergent payer expectations and laboratory capabilities.

The Asia-Pacific region exhibits rapid uptake of innovative diagnostic technologies alongside diverse clinical needs and procurement models. Growing investments in public health screening programs, expanding access to tertiary care, and a strong emphasis on local manufacturing capacity shape commercial approaches. In several jurisdictions, expedited regulatory pathways and active public-private partnerships accelerate adoption, while supply chain localization efforts influence contractual and pricing dynamics. Across all regions, success depends on tailored evidence-generation, close engagement with clinical opinion leaders, and logistical models that account for regional distribution realities.

Competitive dynamics and strategic behaviors among platform incumbents, specialized innovators, and channel partners shaping assay availability and clinical validation

Competitive activity in the CMV testing arena reflects a mix of platform-focused manufacturers, specialized assay developers, and emerging innovators targeting niche clinical applications. Established diagnostic firms tend to compete on portfolio breadth, regulatory track record, and global distribution networks, offering integrated solutions that span high-throughput laboratory systems to point-of-care instrumentation. These incumbents invest in clinical validation studies, cross-platform compatibility, and lifecycle service agreements to maintain customer lock-in and to support hospital and reference laboratory requirements.

Specialized assay developers often differentiate through technical innovation such as enhanced sensitivity, simplified workflows for decentralized testing, or proprietary chemistries that reduce time-to-result. Partnerships between technology pioneers and larger distributors have become a common path to scale, enabling novel assays to reach broader clinical settings while leveraging established sales channels and regulatory expertise. New entrants focused on digital amplification methods or sample-to-answer platforms are reshaping expectations for quantitative performance and operational simplicity.

Across competitive dynamics, service and support models increasingly influence procurement decisions. Buyers value vendors that can provide installation, training, ongoing technical support, and robust quality assurance programs. Strategic behaviors such as co-development agreements with clinical centers, OEM partnerships, and targeted acquisitions are prevalent as firms seek to bolster capabilities quickly and to align product roadmaps with clinical demand signals. For stakeholders monitoring competitiveness, the critical lens is on how firms translate technical claims into validated clinical outcomes, deploy scalable commercial models, and maintain supply continuity under varied policy conditions.

Practical and prioritized actions for industry executives to enhance clinical credibility, resilience, and adoption of cytomegalovirus diagnostic solutions

Industry leaders can act decisively to capture clinical trust, accelerate adoption, and build resilient supply and commercial models in CMV testing. Prioritizing robust clinical validation studies that demonstrate actionable utility across intended applications will strengthen payer and provider confidence. Aligning product design with the operational realities of target end users-such as minimizing hands-on time for clinics or ensuring automation and throughput for diagnostic laboratories-will reduce barriers to adoption and support integration into clinical workflows.

Investing in supply chain resilience is essential; manufacturers should diversify sourcing, consider regional manufacturing partnerships, and design products that can be assembled across multiple jurisdictions to mitigate tariff exposure and logistical disruption. Collaborating with clinical thought leaders and public health authorities to generate guideline-aligned evidence will facilitate inclusion in screening and monitoring protocols. Additionally, companies should evaluate flexible pricing and service bundles that reflect total cost of ownership considerations for buyers, including reagent stability, instrument uptime guarantees, and software interoperability.

Finally, fostering partnerships that enable combined diagnostic and clinical management solutions-such as integrating quantitative viral load reporting with patient monitoring platforms-can create differentiated value for end users. Executing on these actions will require clear prioritization, cross-functional coordination between R&D, regulatory, and commercial teams, and disciplined investment in evidence generation and customer support infrastructure.

Transparent, reproducible research approach combining rigorous secondary evidence review with primary stakeholder interviews and scenario-based validation

This research utilized an evidence-driven methodology combining systematic secondary literature review with primary qualitative interviews to ensure balanced and reproducible findings. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, and technical white papers to map assay performance characteristics, recommended clinical workflows, and validation standards. Primary research included structured interviews with clinicians, laboratory directors, procurement managers, and technology developers to capture firsthand perspectives on adoption drivers, operational constraints, and unmet needs.

Analytical frameworks were applied to synthesize insights across segmentation axes and geographies, ensuring that technology assessments were grounded in clinical applicability and laboratory realities. Triangulation techniques validated claims by cross-referencing instrument specifications, regulatory approvals, and clinical outcome studies. Scenario analysis was used to explore supply chain disruptions and policy shifts, while qualitative coding of interview responses identified recurring themes related to usability, evidence expectations, and service requirements.

All findings were subjected to internal peer review and cross-functional validation to enhance robustness and to reduce bias. The methodology emphasized transparency in source attribution and reproducibility of analytic steps, enabling stakeholders to assess the evidentiary basis for conclusions and to adapt frameworks for internal use.

Consolidated conclusions emphasizing validated innovation, operational resilience, and evidence-driven adoption as the pillars for effective cytomegalovirus diagnostic strategies

CMV diagnostics occupy a dynamic intersection of clinical need, technological innovation, and operational imperatives. Advances in molecular amplification and point-of-care antigen detection are expanding the settings and use cases where timely CMV identification can materially influence outcomes for neonates, transplant recipients, and pregnant patients. At the same time, regulatory rigor, supply chain constraints, and regional heterogeneity demand that developers and adopters pursue evidence-driven, flexible strategies that prioritize clinical utility and service continuity.

Decision-makers should orient product development and procurement around demonstrable improvements in patient management, ease of integration into existing workflows, and resilience against policy- or logistics-driven disruptions. By doing so, stakeholders can ensure that investments in diagnostics translate into measurable clinical benefits and sustainable commercial returns. The net effect is a landscape that rewards validated innovation, operational pragmatism, and collaborative approaches to evidence generation and distribution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cytomegalovirus Tests Market, by Product

  • 8.1. Antigen Detection Test
    • 8.1.1. Immunofluorescence Assay
    • 8.1.2. Lateral Flow Assay
  • 8.2. Nucleic Acid Amplification Test
    • 8.2.1. Digital Polymerase Chain Reaction
    • 8.2.2. Isothermal Amplification
    • 8.2.3. Real Time Polymerase Chain Reaction
  • 8.3. Serological Assay
    • 8.3.1. Chemiluminescent Immunoassay
    • 8.3.2. Enzyme Linked Immunosorbent Assay
    • 8.3.3. Lateral Flow Immunoassay

9. Cytomegalovirus Tests Market, by Test Type

  • 9.1. Qualitative
  • 9.2. Quantitative

10. Cytomegalovirus Tests Market, by Sample Type

  • 10.1. Saliva
  • 10.2. Tissue
  • 10.3. Urine
  • 10.4. Whole Blood

11. Cytomegalovirus Tests Market, by Application

  • 11.1. Diagnostic
  • 11.2. Donor Screening
  • 11.3. Prenatal Testing
  • 11.4. Screening

12. Cytomegalovirus Tests Market, by End User

  • 12.1. Clinic
  • 12.2. Diagnostic Laboratory
  • 12.3. Hospital
  • 12.4. Research Institute

13. Cytomegalovirus Tests Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cytomegalovirus Tests Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cytomegalovirus Tests Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cytomegalovirus Tests Market

17. China Cytomegalovirus Tests Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbexa Ltd.
  • 18.6. Abbott Laboratories
  • 18.7. Accubiotech Co., Ltd
  • 18.8. AdvaCare Pharma USA
  • 18.9. Agilent Technologies, Inc.
  • 18.10. Atlas Medical GmbH
  • 18.11. Bio-Rad Laboratories, Inc.
  • 18.12. Biogenix Inc. Pvt. Ltd.
  • 18.13. CLONIT srl
  • 18.14. Creative Diagnostics
  • 18.15. CTK Biotech Inc. by SSI Diagnostica A/S
  • 18.16. Diasorin S.p.A.
  • 18.17. Elabscience Bionovation Inc.
  • 18.18. F. Hoffmann-La Roche Ltd.
  • 18.19. Hangzhou Realy Tech Co., Ltd.
  • 18.20. Intec Products, Inc.
  • 18.21. IQ Products B.V.
  • 18.22. Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
  • 18.23. Meridian Bioscience, Inc. by SD Biosensor
  • 18.24. Thermo Fisher Scientific Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 170. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 171. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 198. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 199. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 206. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 207. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 208. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 209. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)